Fourth ventricular ependymoma with a distant intraventricular metastasis: Report of a rare case

Sudheer Ambekar, Manish Ranjan, Chandrjit Prasad¹, Vani Santosh², Sampath Somanna

Departments of Neurosurgery, ¹NeuroImaging and Interventional Radiology, and ²Neuropathology, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka, India

ABSTRACT
Ependymoma is one of the uncommon tumors of the central nervous system (CNS) in the adult age group. These tumors have a distinct propensity for metastasis, both within and outside the CNS. However, dissemination at the time of first presentation and retrograde dissemination of the tumor is rare. We report the case of a patient with fourth ventricular anaplastic ependymoma who presented with left lateral ventricular metastasis which was anatomically different from the primary tumor. We describe the clinic-pathological detail of the patient and discuss the probable pathophysiological basis for this rare presentation and its significance in management of the patient.

Key words: Anaplasia, cerebrospinal fluid, ependymoma, metastasis

Introduction
Ependymomas constitute 2-9% of all intracranial neoplasms. Of these, about 50% present within the first two decades. Intracranial ependymomas account for one-fourth of the cases in adults. Cerebrospinal fluid (CSF) spread is seen in about 8-33% of patients with ependymoma at presentation,¹ ² and is more common in patients with infratentorial tumors (9.7%) than in those with supratentorial tumors (1.6%) and in patients with high grade tumors (8.4%-20%) than in those with low grade tumors (2-4.5%).³ Lumbosacral region is the most common site for “drop” metastases. We report a patient with fourth ventricular ependymoma with a distant upstream left lateral ventricular metastatic lesion, a rare phenomenon not described in literature so far, in spite of the tumor being and closely related to the ventricular system.

Case Report
A 23-year-old man presented with progressive swaying to either side while walking for five months and progressive headache associated with vomiting for four months prior to presentation. There was no history of seizures, diplopia or similar illness in family members. Examination revealed bilateral papilloedema and bilateral cerebellar signs. The patient was initially evaluated by a general practitioner at local hospital with computed tomography (CT) of the head. It revealed a midline posterior fossa mass lesion, isodense on non-contrast CT and enhancing heterogeneously on contrast injection with obstructive hydrocephalus. He was subsequently referred to our hospital. The patient was first seen at our hospital two months after the initial CT scan. Magnetic Resonance Imaging (MRI) of the brain done about 2 months after initial CT showed increase in the size of the tumor which was isointense on T1WI and T2WI and enhancing heterogeneously on gadolinium contrast injection. The lesion was completely intra-fourth ventricular [Figure 1]. Another lesion was noted in the septum pellucidum extending to the frontal horn of the left lateral ventricle causing obstruction of the foramen of Monro on the left side [Figure 2]. It had the same signal characteristics as that of the tumor. This lesion was not present in the initial CT scan [Figure 3], which was done two months prior to the MRI. There were no other lesions seen on craniospinal MRI.

In view of severe symptoms of raised intracranial pressure, he initially underwent ventriculo-peritoneal shunt placement followed by midline sub-occipital craniectomy and near total excision of the tumor except...
for the part adherent to the brainstem. Post-operatively, he recovered well.

Histopathological examination showed a cellular glial neoplasm consisting of proliferating ependymal cells arranged in compact sheets and several intervening perivascular rosettes. The cells exhibited brisk mitotic activity (6 to 7 in 10 high power fields) with areas of necrosis [Figure 4]. These features suggested a diagnosis of anaplastic ependymoma (grade III).

The patient was subsequently referred to radiation oncologist for adjuvant therapy.

**Discussion**

Ependymoma is a rare tumor of neuroectodermal origin arising from ependymal cells in the obliterated central canal of the spinal cord, the filum terminale, choroid plexus and white matter adjacent to the ventricles. Migration of fetal ependymal cell rests from periventricular areas into parenchyma may account for parenchymal location of these tumors in some instances. Histopathological examination shows moderate cellularity, rare mitoses and monomorphic cellular morphology. Perivascular pseudorosettes and ependymal canals are important histological features. The four variants described are cellular, papillary, clear cell and tanycytic ependymoma. Anaplastic ependymoma is characterized by hypercellularity, cellular and nuclear pleomorphism, frequent mitosis, pseudopalisading necrosis and endothelial proliferation. Metellus et al., in their study noted three histological factors namely presence of necrosis, microvascular proliferation and mitotic count greater than 5 to be associated with tumor recurrence, metastasis and short progression-free survival in adult patients with intracranial ependymoma. Wolfsberger et al., in a multivariate analysis, also noted...
a high risk of tumor recurrence and worse outcome in patients whose tumors demonstrated a high Ki-67 index than in those with a low index.

Being uncommon in adults, it is difficult to assess the outcome of ependymomas in an adult population. Adults seem to have better prognosis than children with a 5-year survival of 55-90% and 14-60%, respectively. Various factors have been associated with prognosis of patients with ependymoma such as age, sex, location, tumor grade, extent of resection, treatment modalities, local or craniospinal radiation, chemotherapy, gain of 1q and low nucleolin expression by the tumor cells. Of these only the extent of resection has been known as the most important and consistent prognostic factor. From these studies, high Ki-67 index has been associated with a worse outcome. Higher grade of tumor is associated with poor outcome and various tumor characteristics are described in prognosticating the individual tumor. One of the common prognostic markers of outcome and the tumor aggressive behavior is a high Ki-67 labeling index. Our patient had brisk mitosis and during surgery had intratumoral necrosis suggesting an aggressive nature of the tumor. Aggressive and the metastatic nature of the tumor have been described in literature in association with various adhesion molecules and the factors affecting the intrinsic cellular pathway. Cadherins are calcium dependent cell adhesion molecules implicated in tumor spread. Decreased expression of N-cadherin has been reported in patients with ependymoma with CSF dissemination. The ADAMs (A Disintegrin AND Metalloproteinase) are a family of membrane proteins that have potential to be key modulators of cell-matrix interactions through the activities of their constituent domains. ADAMs 8, 12, 19 are significantly upgraded in ependymoma, particularly in the anaplastic variety and are known to be associated with more invasive behavior. Decreased expression of antioxidant enzymes in the ependymal tumors are also known to be associated with aggressive nature of the tumor, in particularly with the adult patients. Though we did not have assay of the intrinsic biological markers, the inherent tumor characteristics might have a role in the more aggressive nature of this tumor which was reflected as necrosis during surgery and brisk mitosis on histopathology. Metastasis to the lateral ventricle possibly represents breakdown of the adhesion molecules in a highly aggressive tumor causing CSF seeding to the third ventricular ependymoma along a path of least resistance in the presence of fourth ventricular obstruction.

Larger studies are required to assess the factors predicting the aggressive behavior of these tumors.

**Conclusion**

Ependymomas are uncommon tumors in adults. Defining the extent of the disease pre-operatively and gross total excision of the tumor whenever possible, followed by radiotherapy should be the standard of care in the present day. Metastasis is important in predicting the clinical outcome. Distant intra ventricular metastasis represents a rare pathomorphology and possibly aggressive potential of the tumor.

**References**

1. Qian X, Goumnerova LC, De Girolami U, Gihos ES. Cerebrospinal fluid...
cytology in patients with ependymoma: A bi-institutional retrospective study. Cancer 2008;114:307-14.
2. Salazar OM. A better understanding of CNS seeding and a brighter outlook for postoperatively irradiated patients with ependymomas. Int J Radiat Oncol Biol Phys 1983;9:1231-4.
3. Yuh EL, Barkovich AJ, Gupta N. Imaging of ependymomas: MRI and CT. Childs Nerv Syst 2009;25:1203-13.
4. Oppenheim JS, Strauss RC, Mormino J, Sachdev VP, Rothman AS. Ependymomas of the third ventricle. Neurosurgery. 1994;34:350-2.
5. Centeno RS, Lee AA, Witter J, Barba D. Supratentorial ependymomas. Neuroimaging and clinicopathological correlation. J Neurosurg 1986;64:209-15.
6. Louis DN OH, Wiestler OD, Cavenee WK. Ependymal tumors. In: Lendon RE WO, Kros JM, Korshunov A, Ng HK, editors. WHO classification of tumors of central nervous system. Lyon Cedex: International Agency for Research on Cancer; 2007. p. 74-80.
7. Metellus P, Barrie M, Figarella-Branger D, Chint O, Giorgi R, Gouvernet J, et al. Multicentric French study on adult intracranial ependymomas: Prognostic factors analysis and therapeutic considerations from a cohort of 152 patients. Brain 2007;130(Pr 5):1338-49.
8. Wolfsberger S, Fischer I, Hofberger R, Birner P, Slave I, Dieckmann K, et al. Ki-67 immunolabeling index is an accurate predictor of outcome in patients with intracranial ependymoma. Am J Surg Pathol 2004;28:914-20.
9. Shim KW, Kim DS, Choi JU. The history of ependymoma management, Childs Nerv Syst 2009;25:1167-83.
10. Reni M, Brandes AA. Current management and prognostic factors for adult ependymoma. Expert Rev Anticancer Ther 2002;2:537-45.
11. Verstegen MJ, Leenstra DT, JlJst-Keizers H, Bosch DA. Proliferation- and apoptosis-related proteins in intracranial ependymomas: An immunohistochemical analysis. J Neurooncol 2002;56:21-8.
12. Figarella-Branger D, Lepidi H, Poncet C, Gambarelli D, Bianco N, Rougon G, et al. Differential expression of cell adhesion molecules (CAM), neural CAM and epithelial cadherin in ependymomas and choroid plexus tumors. Acta Neuropathol 1995;89:248-57.
13. Yokoi K, Akiyama M, Yanagisawa T, Takahashi-Fujigasaki J, Yokokawa Y, Mikami-Terai Y, et al. Sequential analysis of cadherin expression in a 4-year-old girl with intracranial ependymoma. Childs Nerv Syst 2007;23:237-42.
14. Jarvela S, Nordfors K, Jansson M, Haapasalo J, Helen P, Paljarvi L, et al. Decreased expression of antioxidant enzymes is associated with aggressive features in ependymomas. J Neurooncol 2008;90:283-91.

How to cite this article: Ambekar S, Ranjan M, Prasad C, Santosh V, Somanna S. Fourth ventricular ependymoma with a distant intraventricular metastasis: Report of a rare case. J Neurosci Rural Pract 2013. 4(Suppl 1):s121-4.

Source of Support: Nil. Conflict of Interest: None declared.